RxDoctor Payments Data

Forest Mealey, DO

Pulmonary Disease · Monterey, CANPI 1780664136

Payments from drug & device makers

$228,057in general payments, 2019–2025

Across 54 payments — averaging $4223.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$214K
  • Genentech, Inc.$11K
  • Intuitive Surgical$1K
  • Olympus Corporation Of The Americas$956
  • Actelion Pharmaceuticals US, Inc.$211
  • GSK$144
  • plus $551 from 12 others

What the payments were for

  • Travel & lodging$1,73057%
  • Food & beverage$1,15138%
  • Education$1234%
  • Gifts$90%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$228,057 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$145,500
Medicare patients
339
Services billed
1,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DuleraMometasone/Formoterol40$13,782
SymbicortBudesonide/Formoterol Fumarate30$8,887
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$8,828
Combivent RespimatIpratropium/Albuterol Sulfate13$7,020
Incruse ElliptaUmeclidinium Bromide20$6,718
BreynaBudesonide/Formoterol Fumarate37$5,869
Breo ElliptaFluticasone/Vilanterol15$5,577
Albuterol Sulfate HfaAlbuterol Sulfate29$1,119
Fluticasone Propionate40$509
Dexamethasone19$168
Prednisone20$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckDulera$14$13,78240 claims
GSKIncruse Ellipta, Breo Ellipta$144$12,29535 claims
AstraZenecaSymbicort$58$8,88730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →